Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients

  1. Milou A.M. Stals
  2. Marco J.J.H. Grootenboers
  3. Coen van Guldener
  4. Fleur H.J. Kaptein
  5. Sander J.E. Braken
  6. Qingui Chen
  7. Gordon Chu
  8. Erik M. van Driel
  9. Antonio Iglesias del Sol
  10. Evert de Jonge
  11. K. Merijn Kant
  12. Fleur Pals
  13. Myrthe M.A. Toorop
  14. Suzanne C. Cannegieter
  15. Frederikus A. Klok
  16. Menno V. Huisman

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1002/rth2.12496
  2. ScreenIT

    SciScore for 10.1101/2020.12.18.20248265: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementConsent: Informed consent was obtained by an opt-out approach.
    IRB: This study was approved by the Institutional Review Boards of the LUMC for observational studies.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    SPSS Statistics version 25.0 and R version 4.0.2 served for data analysis.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Limitations of our study regarding influenza data are that not all baseline patient characteristics were available, since these could only be determined during a specific time period before hospital admission, and that exact dates of thrombotic complications were not available. Furthermore, we do not know whether, and if so, which dose thrombosis prophylaxis was given to the hospitalized influenza patients. National guidelines in the Netherlands recommend pharmacological thromboprophylaxis with low molecular weight heparin (LMWH) in ward admitted patients in the case of a PADUA Prediction Score ≥ 4 and in the absence of contra-indications. All patients admitted to the ICUs receive pharmacological thromboprophylaxis, irrespective of the PADUA Prediction Score.[31] Standard practice in the LUMC, Amphia Hospital and Alrijne Hospital is the administration of nadroparin 2850 IU sc. per day. It is likely that these recommendations were followed for the hospitalized influenza patients, but still we do not know for sure. In addition, outcome classification differed between influenza and COVID-19 patients, as information on thrombotic complications was identified in influenza based on ICD codes and in COVID-19 by patient chart review. Besides, it is important to recall that thrombotic risks in influenza may differ between the seasonal influenza virus – from which patients were included in this study - and the H1N1 influenza virus pandemic from the year 2009/2010. For COVID-19 data, li...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.12.18.20248265v1 on medRxiv